secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cosmos Health Inc. (COSM)
CIK:        0001474167
Form:       8-K
Filed at:   2026-10-09T21:00:16+00:00
Accession:  0001477932-26-006158
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cosmos Health prelim 9-month revenue $54.3M, up 19% YoY; Q3 record $17.4M; FY2026 outlook >$90M reaffirmed
--------------------------------------------------------------------------------

- Preliminary nine-month revenue of ~$54.3M, up 19%, or $8.7M, from $45.6M in the first nine months of 2025; figures are unaudited.
- Q3 revenue ~$17.4M vs $17.1M in Q3 2025 (+2%) and $12.4M in Q3 2024 (+40%); Q1, Q2 and Q3 2026 each set a new record for that period.
- Nine-month revenue roughly matches full-year 2024 revenue of $54.4M and equals 83% of record full-year 2025 revenue of $65.3M.
- FY2026 revenue outlook reaffirmed at over $90M (+~38% vs 2025), with Q4 2026 expected to be the strongest quarter in company history.
- Cana Laboratories' contract-manufacturing pipeline hit a record >32.7M units; CosmoFarm distributes to >1,500 pharmacies; Sky Premium Life, C-Scrub and C-Sept brands entered new markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1474167/000147793226006158/0001477932-26-006158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1474167/000147793226006158/cosm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-006158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer